The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
|Articles|April 2, 2015
- Pharmaceutical Technology-04-02-2015
- Volume 39
- Issue 4
Meissner Biocontainer Increases Customizability
Meissner’s TepoFlex is a polyethylene biocontainer designed for secure handling and it is part of the One-Touch single-use systems portfolio.
Meissner’s TepoFlex is a polyethylene biocontainer designed for secure handling and it is part of the One-Touch single-use systems portfolio. Available in standard assembly designs of 50 mL–1000 L, the biocontainers can be fitted with customized tube lengths, connectors, and end fittings.
To fit existing rigid outer containers and biomanufacturing systems, custom biocontainers can be designed. The biocontainers, which serve applications from process development through production, are designed with the same materials throughout the entire portfolio to streamline scale-up efforts when ordering new parts.
Articles in this issue
over 11 years ago
Evaluating Package Integrityover 11 years ago
Designing Trouble-Free Freeze-Drying Processesover 11 years ago
Modernizing Scale-Upover 11 years ago
Ross Discharge System Increases Efficiencyover 11 years ago
West Vial Seal Reduces Risk of Contaminationover 11 years ago
Quattroflow Diaphragm Pump Ensures Product Containmentover 11 years ago
Industry Expert Q&A with David Barrettover 11 years ago
The Role of Regulatory Advice in Drug DevelopmentRelated to this article
The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.